Related Experiment Videos
Renal vascular effects of calcium channel blockers in hypertension
1Department of Medicine, New York University School of Medicine, New York City.
Insights
Calcium channel blockers impact renal hemodynamics in hypertension and chronic kidney disease. These drugs may slow kidney damage progression by influencing vasoconstriction and other factors.
Area of Science:
- Nephrology
- Pharmacology
- Cardiovascular Medicine
Background:
- Hypertension and chronic renal failure are associated with altered renal hemodynamics.
- Calcium channel blockers are widely used for hypertension management.
- Emerging evidence suggests potential renoprotective effects of calcium channel blockers.
Purpose of the Study:
- To review the effects of calcium channel blockers on renal hemodynamics in hypertension.
- To evaluate the impact of calcium channel blockers on the progression of chronic renal disease.
- To explore the mechanisms underlying the potential renoprotective actions of these agents.
Main Methods:
- In vitro studies examining the reversal of vasoconstriction induced by catecholamines and angiotensin II.
- In vivo studies in patients with human hypertension.
- Analysis of experimental models of chronic renal disease.
Main Results:
- In vitro, calcium channel blockers reversed afferent arteriolar vasoconstriction, potentially increasing glomerular filtration rate while maintaining low renal blood flow.
- In vivo human studies showed lowered renal resistance and potential increases in renal blood flow and glomerular filtration rate.
- Experimental models demonstrated slowed progression of renal damage, though hemodynamic effects varied.
Conclusions:
- Calcium channel blockers demonstrate multifaceted effects on renal hemodynamics in hypertension.
- These agents may slow the progression of chronic renal damage through various mechanisms.
- Further research suggests potential protective roles for calcium channel blockers in patients with both hypertension and chronic renal disease.
Abstract:
Recent evidence suggests that calcium channel blockers have specific effects on renal hemodynamics in patients with hypertension and may also slow the progression of chronic renal failure. When these agents are studied in vitro, their predominant effect is to reverse afferent arteriolar vasoconstriction induced by catecholamines or angiotensin II. Because efferent resistance may remain high, glomerular filtration rate rises while renal blood flow remains low. The effects in vivo are less consistent. In human hypertension, calcium channel blockers lower renal resistance and may raise both renal blood flow and glomerular filtration rate. In experimental models of chronic renal disease, calcium channel blockers slow the progression of renal damage; however, variable effects on renal hemodynamics have been found. Other factors implicated in the progression of renal damage, including compensatory renal hypertrophy, platelet aggregation, and calcium deposition, may also be favorably influenced by these agents. Recent studies suggest that calcium channel blockers may have similar protective effects in patients with hypertension and chronic renal disease.